Pulmonary Covid Fibrosis a New Pharmaceutic Approach

BACKGROUND: Patient's post-COVID may develop chronic irreversible respiratory failure with “widespread signs of pulmonary fibrosis.” Our study analyzed the causes of this fibrosis to propose a therapeutic protocol. METHODS: Identification of the biochemical causes of fibrosis in COVID-19 analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Menicagli, Roberto, Limodio, Mario, Limodio, Marta, Casotti, Maria Teresa, Menicagli, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218809/
https://www.ncbi.nlm.nih.gov/pubmed/34249284
http://dx.doi.org/10.4103/ijpvm.IJPVM_462_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218809/
https://www.ncbi.nlm.nih.gov/pubmed/34249284
http://dx.doi.org/10.4103/ijpvm.IJPVM_462_20

Ejemplares similares